Every material Form 8-K Orthofix Medical Inc. has filed with the SEC since June 11, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Orthofix reported third-quarter 2026 net sales of $207.9 million, up 1.1% from $205.6 million a year earlier, and a net loss of $6.1 million, narrowed from $22.8 million. The company lowered its full-year 2026 net sales guidance to $825 million to $830 million from $845 million to $855 million, and its adjusted EBITDA guidance to $86 million to $88 million from $95 million to $98 million, citing weaker U.S. Spine performance.
Q3 2026 net sales were $207.9 million, up 1.1% reported and 2.3% pro forma constant currency; Global Limb Reconstruction rose 8.5% and Spinal Implants, Biologics and Enabling Technologies fell 1.1%.
Q3 net loss was $(6.1) million, or $(0.15) per share, versus $(22.8) million, or $(0.57) per share, a year earlier; adjusted EBITDA was $26.0 million versus $24.6 million.
2026 net sales guidance was cut to $825 million–$830 million; adjusted EBITDA guidance was cut to $86 million–$88 million.
Cash, cash equivalents and restricted cash were $86.9 million at September 30, 2026, down from $104.4 million at June 30, 2026.
Orthofix reported second-quarter 2026 net sales of $210.9 million, up 3.8% from a year earlier, but its net loss widened to $15.8 million from $14.1 million and adjusted EBITDA fell to $20.1 million from $20.6 million. The company raised its full-year 2026 guidance for net sales and adjusted EBITDA, but cash declined to $104.4 million as it made arbitration award and settlement payments to three former executives.
Q2 2026 net sales were $210.9 million, up 3.8% reported and 4.7% pro forma constant currency versus Q2 2025.
Q2 net loss was $(15.8) million, or $(0.39) per share, compared with $(14.1) million, or $(0.36) per share, a year earlier.
2026 guidance raised: net sales to $845 million–$855 million (from $838 million–$848 million) and adjusted EBITDA to $95 million–$98 million (from $90 million–$93 million), both set May 21, 2026.
Cash, cash equivalents and restricted cash fell to $104.4 million on June 30, 2026, from $120.9 million on March 31, 2026.
On July 1, 2026, the Centers for Medicare & Medicaid Services withdrew billing and fee schedule changes that followed the FDA's April 16, 2026 reclassification of non-invasive bone growth stimulators. Orthofix now expects average Medicare reimbursement for the affected codes to return to the rates in effect before May 18, 2026. The filing gives no dollar figures for the expected impact.
FDA final order on April 16, 2026 reclassified non-invasive bone growth stimulators from Class III to Class II devices.
CMS changes to billing and Medicare fee schedule treatment applied to HCPCS codes E0747, E0748 and E0760 for dates of service on or after May 18, 2026.
On July 1, 2026, CMS withdrew those changes and directed that devices furnished on or after May 18, 2026 be paid as before the reclassification.
Orthofix expects average Medicare reimbursement for these codes to return to pre-May 18, 2026 rates; no dollar amounts were disclosed.
At its June 10, 2026 annual meeting, Orthofix Medical shareholders elected all 10 director nominees to one-year terms, approved an advisory vote on executive compensation, ratified Ernst & Young LLP as auditor for 2026, and approved Amendment No. 5 to the Second Amended and Restated Stock Purchase Plan. The plan amendment adds 1,250,000 shares available for issuance under the plan, in which the company's named executive officers participate. The filing reports no other changes to the plan.
Ten directors were elected for terms ending at the 2027 annual meeting; Wayne Burris and Michael E. Paolucci each drew more than 5 million votes against.
Stock purchase plan amendment adds 1,250,000 shares; approved by 29,235,005 votes for and 831,625 against.
Executive compensation advisory vote passed with 24,480,474 votes for and 5,577,200 against.
Ernst & Young LLP ratified as independent auditor for the year ending December 31, 2026, with 33,262,505 votes for.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Orthofix Medical Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →